. Author manuscript; available in PMC: 2019 Jul 1.

Published in final edited form as: Int J Gynecol Cancer. 2018 Jul;28(6):1077–1084. doi: 10.1097/IGC.0000000000001271

Table 3.

Utility weights used for quality-adjusted life-years in decision tree analysis of neoadjuvant chemotherapy versus primary debulking surgery in bulky advanced epithelial ovarian cancer

	Utility weight		Time frame (months)
	PDS	NACT	Time frame (months)	Source
Neoadjuvant chemotherapy	–	0.58	2.08	Fagotti et al[26]
Post-surgery + 3 rounds ACT	0.48	0.66	3.07	Fagotti et al[26]
ACT (rounds 4-6)	0.57	–	2.08	Fagotti et al[26]
no ACT following PDS	0.28	–	2.70	Havrilesky et al[35]
no IDS following NACT	–	0.16	8.42	Havrilesky et al[35]
Death	0.00	0.00	varies
>1 year post-treatment	0.83	0.83	varies^*	Havrilesky et al[35]

Abbreviations: ACT, adjuvant chemotherapy; PDS, primary debulking surgery; IDS, interval debulking surgery; NACT, neoadjuvant chemotherapy

Utility weight applied to all survival time beyond 1 year (threshold analysis)